| abstract |
The present invention discloses halogen substituted phenylate compounds and uses thereof. Specifically, the present invention provides a compound represented by formula (I) or an optical isomer, pharmaceutically acceptable salt, prodrug, hydrate or non-aqueous solvate thereof. Compared with the control compound MGL-3196, the compound represented by formula (I) obtained through a specific substitution position and specific substitution type of the present invention has better agonistic activity against THR-β, and THR-β/THR-α It has been proven by experiments that the selectivity for In addition, the compounds of the present invention also have significantly improved pharmacokinetic properties. The compounds of the present invention have excellent application prospects in the manufacture of drugs to treat THR-β agonists and indications to which THR-β agonists are applied (including dyslipidemia, hypercholesterolemia, nonalcoholic steatohepatitis, nonalcoholic fatty liver disease) . (I) |